1056-1057 / 3581
Primary endpoint
•
Acute non-genitourinary grade 3 or greater toxicity (up to 3 months
following treatment completion)
Secondary endpoints
•
Local disease control rate at 3 months
•
Control rate of presenting symptoms
Endpoints
•
Patient reported outcomes
•
Late toxicity
•
Time to local disease progression
•
Overall survival
•
Proportion of fractions benefiting from adaptive planning
•
Appropriate identification and correction of fractions requiring
adaptive planning
in partnership with